2197.HK HKSE
Clover Biopharmaceuticals, Ltd.
1W: -13.1%
1M: -12.2%
3M: +4.7%
YTD: -22.8%
1Y: +179.7%
3Y: +84.5%
HK$1.86 ($0.24)
+0.08 (+4.48%)
Weekly Expected Move ±8.9%
HK$1
HK$2
HK$2
HK$2
HK$2
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$458M
-43.6% ▼
5Y CAGR: -17.3%
Total Liabilities
$2.3B
-7.9% ▼
5Y CAGR: +0.8%
Shareholders Equity
-$1.8B
-9.9% ▼
Cash & Investments
$286M
-33.1% ▼
5Y CAGR: -18.7%
Total Debt
$11M
-88.2% ▼
5Y CAGR: -13.8%
Net Debt
-$261M
+16.3% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $2.8B | $1.6B | $736M | $401M | $272M |
| Short-Term Investments | $99M | $33M | $30M | $26M | $15M |
| Cash & ST Investments | $2.9B | $1.6B | $766M | $428M | $286M |
| Net Receivables | $0 | $135M | $24M | $46M | $3K |
| Inventory | $769M | $2.4B | $697M | $11M | $10M |
| Other Current Assets | $0 | $230M | $412M | $152M | $40M |
| Total Current Assets | $5.1B | $4.4B | $1.9B | $663M | $336M |
| Property, Plant & Equip. | $222M | $242M | $162M | $116M | $95M |
| Goodwill & Intangibles | $14M | $35M | $40M | $33M | $28M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Assets | $33M | $28M | $0 | $0 | $0 |
| Total Non-Current Assets | $269M | $305M | $202M | $150M | $122M |
| Total Assets | $5.3B | $4.7B | $2.1B | $813M | $458M |
| — Liabilities — | |||||
| Accounts Payable | $589M | $857M | $248M | $120M | $108M |
| Short-Term Debt | $0 | $294M | $308M | $74M | $11M |
| Deferred Revenue | $0 | $0 | $0 | $0 | $1.6B |
| Other Current Liabilities | $1.4B | $1.6B | $1.6B | $1.6B | $59M |
| Total Current Liabilities | $2.1B | $2.8B | $2.3B | $1.9B | $1.8B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $1.9B | $2.5B | $549M | $538M | $501M |
| Total Non-Current Liabilities | $2.0B | $2.5B | $557M | $541M | $505M |
| Total Liabilities | $4.1B | $5.4B | $2.8B | $2.4B | $2.3B |
| — Equity — | |||||
| Common Stock | $742K | $835K | $838K | $838K | $839K |
| Retained Earnings | -$7.0B | -$9.5B | -$9.6B | -$10.5B | $0 |
| Accumulated OCI | $297M | $270M | -$734M | $253M | $0 |
| Total Stockholders Equity | $1.2B | -$668M | -$733M | -$1.6B | -$1.8B |
| Total Liabilities & Equity | $5.3B | $4.7B | $2.1B | $813M | $458M |
| — Key Metrics — | |||||
| Total Debt | $68M | $354M | $334M | $90M | $11M |
| Net Debt | -$2.7B | -$1.3B | -$401M | -$312M | -$261M |
| Total Investments | $99M | $33M | $30M | $26M | $15M |